key: cord-0744985-ssuv806d authors: Santeusanio, Andrew D.; Menon, Madhav C.; Liu, Caroline; Bhansali, Arjun; Patel, Niralee; Mahir, Fahima; Rana, Meenakshi; Tedla, Fasika; Mahamid, Ahmad; Fenig, Yaniv; Zendel, Alexey; Delaney, Veronica; De Boccardo, Graciela; Farouk, Samira S.; Sehgal, Vinita; Khaim, Rafael; Jacobs, Samantha E.; Dunn, Dallas; Sullivan, Timothy; Taimur, Sarah; Baneman, Emily; Florman, Sander; Shapiro, Ron title: Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID‐19) date: 2021-01-21 journal: Clin Transplant DOI: 10.1111/ctr.14221 sha: fb3edb6381d0e0059ba1db1553df8d4e50df00ca doc_id: 744985 cord_uid: ssuv806d The influence of patient characteristics and immunosuppression management on COVID‐19 outcomes in kidney transplant recipients (KTRs) remains uncertain. We performed a single‐center, retrospective review of all adult KTRs admitted to the hospital with confirmed COVID‐19 between 03/15/2020 and 05/15/2020. Patients were followed from the date of admission up to 1 month following hospital discharge or study conclusion (06/15/2020). Baseline characteristics, laboratory parameters, and immunosuppression were compared between survivors and patients who died to identify predictors of mortality. 38 KTRs with a mean baseline eGFR of 52.5 ml/min/1.73 m(2) were hospitalized during the review period. Maintenance immunosuppression included tacrolimus (84.2%), mycophenolate (89.5%), and corticosteroids (81.6%) in the majority of patients. Eleven patients (28.9%) died during the hospitalization. Older age (OR = 2.05; 1.04‐4.04), peak D‐dimer (OR = 1.20; 1.04‐1.39), and peak white blood cell count (OR = 1.11; 1.02‐1.21) were all associated with mortality among KTRs hospitalized for COVID‐19. Increased mortality was also observed among KTRs with concomitant HIV infection (87.5% vs. 36.1%; p < .01). Conversely, immunosuppression intensity and degree of reduction following COVID‐19 diagnosis were not associated with either survival or acute allograft rejection. Our findings potentially support a strategy of individualization of immunosuppression targets based on patient‐specific risk factors, rather than universal immunosuppression reduction for KTRs at risk from COVID‐19. The novel SARS-CoV-2 virus and resulting infectious syndrome termed coronavirus disease 2019 has spread rapidly across the world, leading the World Health Organization to declare a global pandemic in March 2020. 1,2 SARS-CoV-2 transmission occurs primarily through respiratory droplets, with symptoms developing following a median incubation period of 4-5 days. 1, 3, 4 Disease severity ranges from mild or asymptomatic in the majority of patients, to a severe respiratory and inflammatory syndrome and ultimately death in 1%-3% of patients. 1 Solid organ transplant recipients are thought to be at high risk for morbidity and mortality from COVID-19 due to the necessity for chronic immunosuppressive therapy to prevent allograft rejection. 5, 6 However, the optimal immunosuppressant management strategy and potential risk factors for severe COVID-19 disease in solid organ transplant recipients remain relatively unknown. The majority of documented SARS-CoV-2 infections in solid organ transplant patients have been reported in kidney allograft recipients, with mortality rates ranging from 22% to 28% among hospitalized patients. [7] [8] [9] A number of risk factors have been purported to be associated with progression to severe COVID-19 in transplant recipients, including increased age, the presence of chronic comorbidities, and active malignancy; however, the role of chronic immunosuppression remains controversial. 3 This was an IRB-approved, single-center, retrospective cohort study of adult kidney or simultaneous kidney-pancreas transplant recipients with a functioning kidney or pancreas allograft who were admitted to the Mount Sinai Health System with confirmed COVID-19 during a two-month period between 03/15/2020 and 05/15/2020. A waiver of informed consent was granted by the local IRB. Patients were excluded from the review if they received a combined organ transplant other than pancreas or were chronically followed by an outside transplant center. Confirmation of COVID-19 diagnosis was based on RT-PCR testing of a nasopharyngeal swab specimen, using the Roche dual-target assay (one target specific to SARS-CoV-2 and second target for pan-Sarbecovirus), Cobas 6800 instrument. The United States Food and Drug Administration ap- inhibitors are considered as alternative maintenance immunosuppressive agents for patients with a compelling indication for calcineurin inhibitor reduction or avoidance. For standard-risk transplant recipients maintained on tacrolimus therapy, 12-hour whole-blood tacrolimus trough targets are as follows: 10-12 ng/ml for months 1-3, 8-10 ng/ml for months 3-6, 6-8 ng/ml for months 6-12, and 4-6 ng/ml beyond 12 months. A baseline tacrolimus level prior to COVID-19 diagnosis was established for all study patients on maintenance tacrolimus therapy using the median trough value from all reported troughs during the 3 months prior to hospital admission. General institutional recommendations for immunosuppression management upon hospital admission for COVID-19 included a 50% reduction in anti-metabolite dosing as well as a tacrolimus or mTOR target trough level of 4-6 ng/ml. For patients receiving monthly belatacept, doses were held up to 2 weeks from the original scheduled date of administration prior to re-dosing. If COVID-19 symptoms had not improved by 2 weeks, temporary conversion to tacrolimus with a trough target of 4-6 ng/ml was considered. Maintenance corticosteroid doses were continued following hospital admission for COVID-19, and adjunctive corticosteroid boluses were considered for patients with acute respiratory distress syndrome at the recommendation of pulmonary and infectious disease consultants. Protocols regarding antiviral and immunomodulatory treatments for COVID-19 disease evolved over the course of the review period as new data became available. Briefly, a 5-day course of off-label hydroxychloroquine was recommended for patients admitted to hospital with COVID-19 up until 5/4/2020 based on early in vivo reports of efficacy, with the addition of a 3-day course of azithromycin based on the clinical discretion of the treating physician. 11 Either prophylactic or therapeutic anticoagulation was prescribed for patients based on clinical risk, and investigational therapies including convalescent plasma, remdesivir, and interleukin-6 (IL-6) or interleukin-1 (IL-1) inhibitors were considered in consultation with infectious disease and hematology experts. The primary outcome assessed in this review was in-hospital allcause mortality among KTRs diagnosed with COVID-19. Additional secondary endpoints evaluated included patient and allograft survival at 1 month following hospital discharge or study conclusion (6/15/2020), incidence of acute kidney injury during hospitalization (AKI; based on the KDIGO definition of 1.5× increase in baseline serum creatinine over the course of 7 days or urine output <0.5 ml/ kg/h for 6 hours), change in eGFR at 1 month following COVID-19 diagnosis, and the incidence of biopsy-proven acute rejection (BPAR) at any point during the review period. Categorical variables were expressed as raw numbers with percentages, and continuous variables were reported using mean ± standard deviation (SD) or median with interquartile range (IQR). Baseline characteristics and laboratory parameters of KTRs who died in the hospital following admission for COVID-19 were compared with survivors to identify potential predictors of mortality. Continuous variables were compared using the Wilcoxon rank-sum test for non-parametric data, and Fisher's exact test was utilized for categorical variables at α < .05 for significance. Logistic regression generated odds ratios with 95% confidence intervals for pertinent variables, and a multivariable model was built testing all variables significant at the univariate level with Between 03/15/2020 and 05/15/2020, 95 out of 2,126 (4.5%) KTRs followed longitudinally at our transplant center were diagnosed with RT-PCR-confirmed SARS-CoV-2 infection. Of these patients, 69 (72.6%) required hospital admission, 38 of whom were admitted to the Mount Sinai Hospital and comprised the study cohort. The mean age of the cohort was 53.8 ± 13.6 years, and the majority were African American (44.7%) or Hispanic/Latino (34.2%) [complete baseline characteristics are summarized in Table 1 ]. The mean baseline eGFR prior to hospital admission for COVID-19 was 52.5 ± 29.9 ml/min/1.73 m 2 , and maintenance immunosuppression included tacrolimus, mycophenolate, and corticosteroids in 84.2%, 89.5%, and 81.6% of patients, respectively. (Table 2 ). Lymphopenia was also common, with a mean absolute lymphocyte count (ALC) of 587 ± 344 cells/µL observed on admission. Tacrolimus was the primary immunosuppressive agent in 32/38 patients at the time of COVID-19 diagnosis, while 4 patients were receiving belatacept, 1 patient was receiving sirolimus, and 1 patient was on a combination of corticosteroids and immune globulin. Of the 4 patients receiving belatacept, only 1 patient was converted back to tacrolimus during hospitalization. Median tacrolimus trough levels during the hospitalization were reduced by −11% from baseline, although significant variability was observed between patients (IQR = −26% to 17%). Antimetabolite doses were reduced by at least 50% in all but one patient receiving mycophenolate, and 13 (34.2%) patients had their antimetabolite discontinued entirely (Table 3) . Twelve (31.6%) patients received pulse corticosteroids during hospitalization with total doses ranging from 555 to 1914 milligrams (mg) of prednisone equivalents. The most frequently prescribed corticosteroid regimen was methylprednisolone 80 mg daily for a duration ranging from 5 to 10 days. All corticosteroids were prescribed for the indication of COVID-19 pneumonia, and 3 patients additionally Patients experiencing in-hospital mortality were generally older Table S1 ). We did not find that presenting symptomatology or hypoxia on admission was associated with in-hospital mortality in our pa- Immunosuppressant and antiviral management were largely similar between survivors and patients who died, with the exception of higher total corticosteroid doses and more frequent prescription of treatment-dose anticoagulation in patients who died. However, as this likely reflects differences in underlying disease severity rather than treatment efficacy, we performed a subgroup analysis for the The administration of hydroxychloroquine, convalescent plasma, and treatment dose anticoagulation was also not found to be associated with improved survival among our KTRs with severe COVID-19 (Table S2) . The SARS-CoV-2 pandemic has placed a particular burden on immunosuppressed patient populations, including the organ transplant community. 6 to be managed remotely with 100% patient and allograft survival at 1 month. Alternatively, in our cohort of KTRs admitted to hospital, we observed an overall mortality rate of 28%, which is similar to previous reports, and is 2-3× higher than mortality rates reported in the general hospitalized population. 3, 4, [7] [8] [9] While these findings should not preclude kidney transplantation, there is a suggestion that KTRs may be at high risk of significant morbidity and mortality following hospitalization for COVID-19. Among our cohort of KTRs, as has been previously reported, age was independently associated with an approximately 2× higher odds of mortality for each decade of life. 7, 16, 17 We also observed a remarkably high mortality rate in There was a high incidence of AKI in our cohort of KTRs (59.5%). In a meta-analysis by Robbins-Juarez et al, the incidence of AKI following COVID-19 diagnosis ranged from 0.5% to 80.3%, with a mean of 17%. 19 Additionally, a prior report from our own center in non-KTRs reported a 46% incidence of AKI. 20 Kidney transplant recipients diagnosed with COVID-19 are at high risk of poor outcomes following hospitalization, with mortality rates ranging from 22% to 28%. Older age is a significant risk factor for COVID-19-related mortality that has been replicated in a number of studies and was associated with approximately 2× higher odds of death in our patient cohort for each decade of life. We also observed an unusually high rate of mortality in HIV-infected KTRs at our center, which warrants additional study. Baseline symptoms and laboratory values at the time of hospitalization have not been shown to predict COVID-19 mortality, but serum inflammatory markers including D-dimer, CRP, and white blood cell counts should continue to be monitored longitudinally to assess disease course and treatment response. While it has not been explicitly shown to reduce mortality, immunosuppression reduction was not associated with allograft rejection in our study and could be considered on a case-by-case basis. The authors of this manuscript have no conflicts of interest to disclose. The authors did not receive any funding to assist with the completion of this research. MCM acknowledges research and salary support from NIH-NIDDK: RO1-DK122164. None. The data that support the findings of this study are available on request from the corresponding author (Andrew Santeusanio, Mild or moderate COVID-19 Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering Clinical characteristics of coronavirus disease 2019 in China Clinical characteristics of COVID-19 in New York City Novel coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve The COVID-19 outbreak in Italy: initial implications for organ transplantation programs COVID-19 in solid organ transplant recipients: initial report from the US epicenter Covid-19 and kidney transplantation Clinical characteristics and outcomes of COVID-19 in solid organ transplant recipients: a cohort study SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: a national cohort study Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 A serological assay to detect SARS-CoV-2 seroconversion in humans Early impact of COVID-19 on transplant center practices and policies in the United States Organ procurement and transplantation during the COVID-19 pandemic COVID-19 in solid organ transplant: a multi-center cohort study Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19 in the largest US HIV cohort. 23rd International AIDS Conference Virtual Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis Acute kidney injury in hospitalized patients with COVID-19 Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology Dexamethasone in hospitalized patients with COVID-19 -preliminary report Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome Immunosuppressant dose reduction and long-term rejection risk in renal transplant recipients with severe bacterial pneumonia Additional supporting information may be found online in the Supporting Information section.